Read news on pembrolizumab with our app.
Read more in the app
Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC
Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC
Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: Hint of major added benefit - EurekAlert!
Ivonescimab outperforms pembrolizumab in phas - EurekAlert
Improved efficacy of pembrolizumab when combined with sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC - EurekAlert
